The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10439 malaria professionals are enjoying the free benefits of MalariaWorld today

Recent comments

  • Reply to: Modern Explanation for Plasmodium vivax Malarial Recurrences   1 day 5 hours ago

    The immediate outcome of citation inaccuracy is the following (although this is self-evident):

    As indicated somewhere above, it is no secret that other authors in the overall malaria field have likewise experienced unacceptable goings-on in relation to the citation of publications that they have authored. Thus, the curious P. vivax recurrence-related, reference omission phenomenon, both old (going back 4 decades) and more recent, is not unique.

    In cases where non-citation or seemingly devious (dishonest) citation in connection with something "new" (i.e. not yet accepted malariological knowledge) has been inadvertent, this is perfectly understandable if very little had previously been published on the particular malarial topic concerned.

    When there is an existing body of literature, however, the reader cannot necessarily discern, depending partly on the size of the body of literature: (A) Whether inaccurate citation or non-citation was intentional. Or (B) Whether it is purely profound ignorance (of the specific malarial subject area) that is on display.

  • Reply to: Viruses, Malaria, Platelets and Artemisia   1 day 12 hours ago

    In the recent confrontations of  WHO with African governments on the use of Artemisia annua and its infusions as remedies against coronavirus and malaria, Artemisia afra was somewhat neglected in the discussions. Artemisia afra is a local plant growing from the Cape to Ethiopia. It has been used for generations against malaria and other tropical diseases like bilharzia, tinea capitis, Buruli ulcer, tuberculosis, trypanosoma. Many clinical trials made by Africans have confirmed this extraordinary efficacy. This entails that the plant if perfectly legal in African countries in accordance with the WHO prescriptions.

    WHO/EDM/TRM/2000.1      Traditional use refers to documentary evidence that a substance has been used over three or more generations of recorded use for a specific health related or medicinal purpose.

    In this case WHO maintains its position that there is no requirement for pre-clinical toxicity testing.

    Pre-clinical toxicity testing is only required for new medicinal herbal products which contain herbs of no traditional history of use.

    The plant does not contain artemisinin, the molecule used by Bigparma in ACTs. The risk that it may lead to artemisinin resistance is thus absent.

  • Reply to: Modern Explanation for Plasmodium vivax Malarial Recurrences   5 days 20 hours ago

    It is obvious that correct future citing would nip this problem in the bud and, therefore, make it quietly go away.

  • Reply to: Modern Explanation for Plasmodium vivax Malarial Recurrences   6 days 10 hours ago

    Any questionable future citation events concerning this subject (including inaccurate self-citations) will clearly and justifiably go down in history, to the detriment of the citing authors.

  • Reply to: Viruses, Malaria, Platelets and Artemisia   1 week 3 hours ago

    I read that Madagascar plans mass drug administration of IV artesunate, with the approval of WHO. Apparently this highly  hemotoxic product is already available in African pharmacies. Thousands of innocent people risk to be killed.